Shiying Kong

Anti-PD1-Induced Immune-Related Adverse Events and Survival Outcomes in Advanced Melanoma

Aleksi Suo, Yin Chan, Carissa Beaulieu et al. · The Oncologist · 2020 · 75 citations · Full text

Generalisability of Common Oncology Clinical Trial Eligibility Criteria in the Real World

Safiya Karim, Yuan Xu, Shiying Kong et al. · Clinical Oncology · 2019 · 57 citations

Oncology, Clinical Trial Design, Health Policy +11

Development and validation of case-finding algorithms for recurrence of breast cancer using routinely collected administrative data

Yuan Xu, Shiying Kong, Winson Y. Cheung et al. · BMC Cancer · 2019 · 49 citations · Full text

Impact of pre-existing cardiovascular disease on treatment patterns and survival outcomes in patients with lung cancer

Atul Batra, Dropen Sheka, Shiying Kong et al. · BMC Cancer · 2020 · 38 citations · Full text

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database

Heidi A.I. Grosjean, Samantha Dolter, Daniel E. Meyers et al. · Current Oncology · 2021 · 27 citations · Full text